CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 631 enrolled
Drug / intervention
nivolumab monotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03963518
NCT03963518N/ACompleted
CompareCT.gov

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials

Institut Bergonié·observational·Posted May 24, 2019·Updated Oct 6, 2025

In Brief

An observational study evaluating nivolumab monotherapy and nivolumab plus ipilimumab for Cancer Treated With Immune-checkpoint Inhibitors. Completed, enrolled 631 participants across 1 site.

Detailed Summary

Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigate

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer Treated With Immune-checkpoint Inhibitors
CountriesFrance
CollaboratorsInstitut National de la Santé Et de la Recherche Médicale, France

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 24, 2019
Enrollment StartJan 1, 2017
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.1 years ago

Interventions

nivolumab monotherapydrug

nivolumab monotherapy

nivolumab plus ipilimumabdrug

nivolumab plus ipilimumab